

OMB No. 0651-0011 (exp. 4/94)

XH 10A

04-19-2004



To the Honorable Director of the US

102724842

the attached original documents or copy thereof.

1. Name of conveying party(ies):

Bristol-Myers Squibb Company

4-15-04

2. Name and address of receiving party(ies)

Name: University of Oxford

Internal Address: University Offices

Street Address: Wellington Square

City: Oxford, OX1 2JD (Great Britain)

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other

Execution Date:

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B. Patent No.(s)

6,087,118

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Stephen B. Davis

Internal Address: Bristol-Myers Squibb Company

Patent Department

Street Address: P.O. Box 4000

City: Princeton State: NJ ZIP: 08543-4000

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41)

\$ 40

☐ Enclosed☒ Authorized to be charged to deposit account and any other additional fees required.

8. Deposit account number:

19-3880 (in the name of Bristol-Myers Squibb Company)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Burton Rodney

Name of Person Signing
Reg. No. 22,076

Signature

Date

☐ Certificate of mailing on reverse side

Total number of pages including cover sheet, attachments, and document: 2

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services, Director of the US Patent and Trademark Office

PO Box 1450, Alexandria, VA 22313-1450

04/16/2004 BTOM11 00000048 193880 6087118

01 FC:8021

40.00 DA

PATENT
REEL: 015209 FRAME: 0210

ASSIGNMENT OF PATENT

WHEREAS, **Bristol-Myers Squibb Company**, a Delaware corporation, having a place of business at Lawrenceville-Princeton Road, Princeton, NJ 08543-4000, is the sole and exclusive owner by assignment from the inventors of Letters Patent of the United States of America issued to Jeffrey K. Aronson, H. Asita de Silva, David G. Grahame-Smith for

METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE

which Letters Patent is numbered 6,087,118 and bears the date of July 11, 2000; said assignment being recorded at Reel 9549, Frame 0820; and

WHEREAS **University of Oxford**, a University, having a place of business at Wellington Square, Oxford, OX1 2JD (GB), is desirous of acquiring all the right, title and interest which said Bristol-Myers Squibb Company has in, to and under the said Letters Patent;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, said Bristol-Myers Squibb Company hereby assigns, transfers and sells unto said University of Oxford, its successors, legal representatives and assigns, the Letters Patent aforesaid; the same to be held and enjoyed by the said University of Oxford, for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, to the end of the term for which said Letters Patent of the United States is granted or reissued as fully and entirely as the same would have been held and enjoyed by the said Bristol-Myers Squibb Company, if this assignment and sale had not been made; together with all claims for damages by reason of past infringement of said Letters Patent, with the right to sue for and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives.

IN WITNESS WHEREOF, said Bristol-Myers Squibb Company caused this Assignment to be duly executed by its proper officers this 12th day of April, 2004.

Bristol-Myers Squibb Company

By: 
David T. Bonk
VP and Associate General Counsel